Community Health Systems, Inc. (CYH)
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$2.89-0.69%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
Broken: Primary pillar broken — EPS improves toward breakeven in FY27: FY27 EPS -0.46 vs 0.10.
Community Health Systems is growing through acquisitions, completing three deals in 2026. Analysts expect revenue near $11.6 billion in 2026. The company reaffirmed its 2026 earnings guidance despite recent challenges. The stock trades cheaply with a P/E of 3.1, well below peers.
Earnings remain negative with a 2026 EPS estimate of -$0.60. Revenue is expected to decline about 3% next year. Litigation and regulatory risks could pressure margins and growth. Management is volatile and guidance was recently cut.
The market expects about 3% revenue decline and negative EPS in 2026. The stock is cheap versus peers, reflecting elevated risk and fragile quality. Our fair value near $14 aligns with consensus but risks remain.
Breaks if: No acquisitions completed in next 12 months
Breaks if: EPS remains below zero in FY27
Reaffirm and maintain annual earnings per share guidance for fiscal year 2026.
Stated as a priority in 3 of last 3 quarters. The Company reaffirmed its 2026 annual EPS guidance with a low end of $1.19 per share in February 2026 and maintained this guidance through Q2 2026. Actual diluted EPS was $0.51 in Q2 2026 and $0.09 for the first six months, indicating mixed progress relative to guidance.
“2026 guidance should be considered in conjunction with assumptions included herein.”
“The Company’s annual earnings guidance for 2026 is reaffirmed.”
“Included tables setting forth the Company’s 2026 annual earnings guidance.”
Breaks if: Material adverse regulatory ruling or large penalty announced
Breaks if: revenue falls below $11B in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with elements of speculative growth. The current thesis state is intact, supported by recent strong financial performance, but it faces challenges due to management volatility and earnings quality.
The market currently prices CYH as cheap compared to its peers, with a notable expectations gap. This suggests that investors may not fully anticipate the potential risks or rewards associated with the company's future performance.
Fundamentals are likely to show mixed results in the near term, as management works to improve cash flow and maintain earnings guidance. However, the company's recent financial performance has been strong, which may help offset some volatility.
The thesis hinges on key factors such as management's ability to meet EPS guidance and the impact of sector performance on CYH. Additionally, the company's response to potential economic downturns will be crucial.
Over the next 1 to 3 years, CYH's performance will depend on management execution and sector trends. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss is a concern. The company forecasts lower adjusted EBITDA due to softer elective surgeries. This threatens its EPS guidance for 2026.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.